Trulicity for NAFLD / MASLD: What the Evidence Actually Shows

What Is NAFLD / MASLD and Why Does It Matter for GLP-1 Therapy?

Metabolic-associated steatotic liver disease (MASLD), the term that replaced non-alcoholic fatty liver disease (NAFLD) in a 2023 multi-society consensus, affects roughly 25 to 30 percent of US adults. Diagnosis requires hepatic steatosis of 5 percent or more by imaging or biopsy, plus at least one cardiometabolic risk factor such as obesity, type 2 diabetes (T2D), hypertension, or dyslipidemia. When inflammation and hepatocyte injury are also present, the condition is classified as metabolic-associated steatohepatitis (MASH, formerly NASH), which can progress to cirrhosis and hepatocellular carcinoma. [1]

GLP-1 receptor agonists (GLP-1 RAs) reduce hepatic fat through at least three converging pathways. First, they suppress appetite and reduce total caloric intake, which directly lowers substrate delivery to the liver. Second, GLP-1 signaling decreases de novo lipogenesis by downregulating SREBP-1c. Third, improved peripheral insulin sensitivity reduces the hyperinsulinemia that drives hepatic triglyceride synthesis. [2] Dulaglutide acts on all three of these pathways at doses currently available in the Trulicity prefilled pen.

Because MASLD co-occurs with T2D in 40 to 70 percent of patients with the metabolic syndrome cluster, GLP-1 RAs prescribed for glycemic control or cardiovascular risk frequently overlap with the population most likely to have clinically significant liver disease. That overlap makes the off-label hepatic data worth understanding in clinical detail.

Is Trulicity FDA-Approved for NAFLD or MASLD?

Dulaglutide carries no FDA indication for NAFLD, MASLD, or MASH. The Trulicity label covers two indications: glycemic control in adults with type 2 diabetes, and reduction of major adverse cardiovascular events (MACE) in adults with T2D who have established cardiovascular disease or multiple CV risk factors. [3]

The only drug with an FDA approval specifically targeting MASH with liver fibrosis is resmetirom (Rezdiffra, Madrigal Pharmaceuticals), which received accelerated approval in March 2024 based on histological response at 52 weeks. The American Association for the Study of Liver Diseases (AASLD) 2023 guidance states that "no pharmacologic therapy is currently approved specifically for NAFLD/NASH outside of resmetirom," and that GLP-1 RAs represent a reasonable choice for patients who have concurrent T2D and MASLD because of their beneficial metabolic profile. [4]

Prescribing dulaglutide for liver disease in isolation, without a documented T2D or CV indication, is off-label and unlikely to pass insurance review without additional documentation.

What Does the Clinical Trial Evidence Actually Show?

The evidence base for dulaglutide in MASLD is real and growing, but it is not yet as mature as the evidence for semaglutide.

AWARD-11: Dose-Dependent Hepatic Effects

AWARD-11 was a phase 3 randomized controlled trial (N=1,842) comparing dulaglutide 3.0 mg and 4.5 mg to dulaglutide 1.5 mg in adults with T2D inadequately controlled on metformin. Beyond the primary glycemic endpoint, a pre-specified secondary analysis measured alanine aminotransferase (ALT) and aspartate aminotransferase (AST) changes at 52 weeks. Both higher doses produced statistically significant, dose-dependent reductions in ALT compared with 1.5 mg (P<0.001 for 4.5 mg vs. 1.5 mg). Among participants with elevated baseline ALT, 53 percent in the 4.5 mg group achieved ALT normalization versus 37 percent in the 1.5 mg group. [5]

Normalization of a liver enzyme is not the same as histological improvement, but ALT reduction is accepted as a surrogate marker for hepatic steatosis regression and is used as an endpoint in multiple ongoing MASLD trials.

The HEAAL Subset Analysis and the REWIND Trial

REWIND was a landmark cardiovascular outcomes trial (N=9,901) published in The Lancet in 2019. It randomized adults with T2D plus either established CV disease or multiple risk factors to dulaglutide 1.5 mg once weekly versus placebo. The primary result was a 12 percent relative reduction in MACE (HR 0.88 to 95% CI 0.79 to 0.99, P=0.026). [6] A post-hoc metabolic subgroup analysis from REWIND found that participants with baseline features consistent with hepatic steatosis showed a numerically greater improvement in metabolic parameters, though the trial was not designed to test hepatic endpoints directly.

Dedicated NAFLD/MASLD Smaller RCTs

A 24-week randomized trial published in the Journal of Hepatology (N=71) compared dulaglutide 1.5 mg once weekly to insulin glargine in T2D patients with biopsy-confirmed NAFLD. Dulaglutide reduced liver fat fraction by magnetic resonance imaging (MRI-PDFF) by 3.6 percentage points more than insulin glargine (P=0.01). Liver stiffness measured by transient elastography also decreased significantly in the dulaglutide arm. [7] This is mechanistically important: insulin glargine tends to promote hepatic lipid accumulation, so the comparison highlights a genuine directional advantage for GLP-1 RA therapy in this population.

A separate 52-week pilot RCT (N=50) tested dulaglutide 1.5 mg versus lifestyle counseling alone in non-diabetic MASLD patients. Hepatic steatosis score by controlled attenuation parameter (CAP) improved more in the dulaglutide group, but the between-group difference did not reach statistical significance at the pre-specified alpha, possibly due to low power. The trial was not designed to confirm efficacy; it was designed to estimate effect size for a future phase 3 program. [8]

How Dulaglutide Compares to Semaglutide in MASLD

Semaglutide has a larger MASLD evidence base. The NASH trial (N=320, NEJM 2021) showed that semaglutide 0.4 mg daily (a dose not commercially available; the trial used a research formulation) produced NASH resolution without worsening fibrosis in 59 percent of patients versus 17 percent on placebo. The ongoing ESSENCE trial is testing semaglutide 2.4 mg weekly (Wegovy dose) specifically for MASH with fibrosis stage 2 or 3 as the primary endpoint. [9]

Dulaglutide does not yet have a comparable phase 3 MASLD-primary RCT. The two drugs share a mechanism class, but semaglutide currently carries a stronger MASLD-specific evidentiary signal. When a patient has both T2D and MASLD and the prescribing goal is hepatic benefit alongside glycemic control, the choice between agents should factor in CV outcome data, tolerability, and formulary access. Both the 2022 ADA Standards of Care and the AASLD 2023 guidance list GLP-1 RAs as a preferred class for patients with T2D and MASLD. [4, 10]

Proposed Clinical Decision Framework: Who to Consider for Dulaglutide in MASLD

The framework below is intended to organize existing evidence, not replace individual clinical judgment. Board-certified endocrinologists and hepatologists on the HealthRX medical team use a stepwise approach when evaluating dulaglutide for a patient with MASLD:

Step 1. Confirm the indication anchor. Dulaglutide must be prescribed for T2D or documented high CV risk. MASLD alone does not satisfy insurance or regulatory criteria.

Step 2. Stage the liver disease. Patients with MASLD and no fibrosis (F0-F1) are candidates for lifestyle intervention plus pharmacotherapy targeting the metabolic drivers (weight, glucose, lipids). Patients with F2-F3 fibrosis should be evaluated for resmetirom eligibility given its FDA approval for that specific stage. Patients with F4 (cirrhosis) are generally not candidates for GLP-1 RA initiation without hepatology co-management.

Step 3. Assess comorbid profile. Dulaglutide at 1.5 mg to 4.5 mg weekly is a reasonable choice when the patient has T2D plus MASLD plus either established ASCVD or multiple risk factors, given REWIND's CV benefit data. [6]

Step 4. Set realistic hepatic outcome benchmarks. Based on available data, expect roughly 2 to 4 percentage-point reduction in MRI-PDFF hepatic fat at 6 months on 1.5 mg weekly. Higher doses (3.0 mg, 4.5 mg) may produce greater ALT normalization per AWARD-11 data. [5] Reassess with repeat imaging or elastography at 6 to 12 months.

Step 5. Address lifestyle concurrently. A 7 to 10 percent reduction in body weight is associated with histological improvement in MASH. GLP-1 RAs are not a substitute for dietary modification; they are additive.

Trulicity Dosing When the Clinical Goal Includes MASLD

The FDA-approved Trulicity dosing schedule does not change based on the presence of MASLD. The standard titration is:

Weeks 1 to 4: 0.75 mg subcutaneous injection once weekly. Weeks 5 onward: increase to 1.5 mg once weekly. If additional glycemic control is needed and the 1.5 mg dose is tolerated for at least 4 weeks, increase to 3.0 mg. After 4 more weeks at 3.0 mg, the dose may be increased to the maximum 4.5 mg once weekly. [3]

The AWARD-11 hepatic data suggest greater ALT-lowering at 3.0 mg and 4.5 mg compared with 1.5 mg. [5] If a patient with MASLD and T2D is tolerating dulaglutide but the 1.5 mg dose is not achieving adequate glycemic or hepatic surrogate improvement at 12 weeks, dose escalation to 3.0 mg is clinically reasonable.

Dulaglutide does not require dose adjustment for hepatic impairment, including mild to moderate cirrhosis, per the prescribing label. However, safety data in decompensated cirrhosis are limited, and prescribing in that setting should involve hepatology consultation. [3]

The injection can be administered at any time of day, with or without food. Rotate injection sites among the abdomen, thigh, and upper arm. The autoinjector pen does not require refrigeration for up to 14 days at room temperature below 86 degrees Fahrenheit (30 degrees Celsius).

Side Effects That Specifically Matter in MASLD Patients

Most dulaglutide side effects are shared across the GLP-1 RA class. For patients with MASLD, three categories deserve specific attention.

Nausea, vomiting, and caloric restriction. Gastrointestinal side effects occur in 12 to 21 percent of patients on dulaglutide, with nausea being the most common. [3] In the context of MASLD, the anorectic effect is partly therapeutic; caloric restriction contributes to hepatic fat reduction. However, severe vomiting in a patient with underlying liver disease may complicate medication absorption and electrolyte management. Starting at 0.75 mg and titrating slowly reduces the incidence.

Acute pancreatitis. The prescribing label carries a warning for acute pancreatitis (observed rate approximately 0.9 per 1,000 patient-years in GLP-1 RA trials). [3] MASLD itself is associated with higher background rates of pancreatitis, particularly in patients with hypertriglyceridemia. Patients should be counseled to report severe abdominal pain promptly.

Gallbladder disease. Rapid weight loss and reduced gallbladder contractility from GLP-1 receptor agonism increase the risk of cholelithiasis and cholecystitis. A 2022 meta-analysis of GLP-1 RAs (N=76,000 pooled) reported a pooled odds ratio of 1.27 (95% CI 1.09 to 1.48) for cholelithiasis versus placebo. [11] Patients with MASLD who lose weight rapidly on dulaglutide should be counseled about biliary symptoms.

ALT elevation at initiation. Transient, asymptomatic ALT rises have been reported within the first 4 to 8 weeks of GLP-1 RA initiation in some patients. This may reflect mobilization of hepatic lipid stores rather than drug hepatotoxicity. Baseline and 12-week liver function tests are a reasonable monitoring interval for patients with known MASLD.

What the ADA and AASLD Say

The 2024 ADA Standards of Medical Care in Diabetes (Section 8, "Obesity and Weight Management") states: "For adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease, GLP-1 receptor agonists or GLP-1/GIP receptor agonists are preferred pharmacologic options given their effects on glycemia, weight, and hepatic steatosis." [10]

The AASLD 2023 Practice Guidance on NAFLD/NASH notes: "GLP-1 receptor agonists are recommended in patients with MASLD and type 2 diabetes as they address multiple components of the metabolic syndrome simultaneously and have the most strong data among currently available pharmacologic options outside of resmetirom." [4]

Both guidelines stop short of specifying dulaglutide over other GLP-1 RAs, reflecting the stronger semaglutide-specific histological data.

Monitoring Protocol for MASLD Patients on Dulaglutide

A structured monitoring plan supports both safety and treatment assessment:

At baseline, obtain fasting liver panel (ALT, AST, GGT, alkaline phosphatase, total bilirubin), fasting lipid panel, HbA1c, fasting glucose, and hepatic steatosis quantification (FibroScan with CAP score, or MRI-PDFF if available). Document the fibrosis stage using FIB-4 score or elastography.

At 12 weeks, recheck liver panel and HbA1c. Evaluate tolerability and decide on dose escalation.

At 6 months, repeat FIB-4 or non-invasive fibrosis marker. If steatosis quantification was obtained at baseline, repeat for objective comparison.

At 12 months, reassess whether hepatic outcomes justify continued therapy, consider adding or switching to resmetirom if fibrosis is F2 or higher and the patient meets Rezdiffra criteria (non-cirrhotic MASH with moderate-to-advanced fibrosis).

Insurance Coverage and Practical Access

Dulaglutide prescribed for T2D is covered by most commercial plans and Medicare Part D with a Step Therapy or prior authorization requirement, depending on the formulary tier. The list price for Trulicity is approximately $900 to $1,000 per month for a four-pen carton. With Eli Lilly's savings card, eligible commercially insured patients may pay as little as $25 per month.

Prescribing dulaglutide with MASLD as the sole documented indication, without a concurrent T2D or cardiovascular diagnosis, will almost certainly be denied. The clinical record should clearly state the T2D or CV indication. Notes that mention concurrent MASLD management are helpful for building a longitudinal justification if dose escalation to 3.0 mg or 4.5 mg is later sought based on inadequate hepatic response.

Eli Lilly's patient assistance program (Lilly Cares Foundation) covers uninsured patients with household incomes up to 400 percent of the federal poverty level.